Chimeric antigen receptor (CAR) T cell therapy of cancer is generating enormous
enthusiasm. Twenty-five years after the concept was first proposed, major advances in
molecular biology, virology, and good manufacturing practices (GMP)-grade cell production
have transformed antibody-T cell chimeras from a scientific curiosity to a fact of life for
academic cellular immunotherapy researchers and, increasingly, for patients. In this review,
we explain the preclinical concept, outline how it has been translated to the clinic, and draw …